Prescient Healthcare Group

What Prescient Healthcare Group does

Prescient Healthcare Group is a science and insight-led biopharma strategy consultancy that partners with global pharmaceutical and biotechnology companies across the full drug lifecycle, from preclinical development through loss of exclusivity. The firm's offering is organized around six integrated service modules: Customer Understanding (primary market research and behavioral insight), Competitive Intelligence (evidence-based monitoring and benchmarking), Early Asset Strategy / New Product Planning, Scientific Strategy (medical affairs), Brand Building and Commercialization, and Value Demonstration and Market Access. Two proprietary analytical tools, BrandFit for quantitative brand-campaign assessment and ConferenceFit for real-time conference intelligence, sit on top of an AI-enabled competitive intelligence platform, while an AI-augmented strategy development workflow uses generative AI to simulate commercial scenarios and stress-test strategic alternatives while preserving human-led judgment. Client work is led by senior "hands-on" executives and is delivered by a workforce in which over 70% hold advanced life sciences degrees (PhDs, MBAs, or MDs) and senior staff average more than 20 years of industry experience.

The firm operates seven offices across three continents (New York, Boston, London, Manchester, Barcelona, Munich, and New Delhi) and serves 23 of the top 25 biopharmaceutical companies alongside high-growth mid-caps and emerging biotechs, reporting 85% recurrent business and an average client partnership of seven years. Its go-to-market is direct enterprise consulting sold at the senior executive level; engagements are project-based, tailored, and priced accordingly, with no public pricing, self-serve channels, or reseller motion. Since 2021 the firm has been backed by private-equity sponsor Bridgepoint via Bridgepoint Development Capital, which has funded a deliberate platform-consolidation strategy: acquisitions of Strategic North (March 2022), Uptake Strategies (January 2026), and Dolon (March 2026) have added market research, launch excellence, and pricing/market access capabilities respectively, bringing total headcount to approximately 500 specialists across the combined entity.

Commercially, Prescient monetizes through professional-services engagements on the consulting revenue model rather than via software licensing, subscription, or marketplace channels, meaning revenue scales primarily with billable headcount, utilization, and rate card. Recognition includes EcoVadis sustainability medals since 2022, B Corp certification (2025), and UN Global Compact participation since 2023. The company does not have a public listing and revenue figures are not publicly disclosed; the current scope and trajectory therefore rest on disclosed headcount, scale commentary, acquisition cadence, and the continued sponsorship of a single PE backer.

Name

Prescient Healthcare Group

Legal name

Prescient Healthcare Group

Website

https://prescienthg.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

251–500 employees

Short description

Prescient Healthcare Group is a biopharma strategy consultancy of approximately 500 specialists across seven global offices, offering integrated commercial, competitive intelligence, scientific strategy, and market access consulting to top biopharmaceutical companies including 23 of the top 25.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Strategy Consulting

NAICS

Other Scientific and Technical Consulting Services (54169)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Medical Affairs, Scientific Communications & HEOR FSP (HLAGAOAG)

akta.pro secondary industries

Medical Affairs Scientific Communications (MSL Support/Scientific Response) (HLAGALAF), Healthcare & Life Sciences PR (BPAFADAJ)

Keywords

• Biopharma strategy consulting
• Pharmaceutical commercial strategy
• Competitive intelligence pharma
• Drug lifecycle consulting
• Market access consulting

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices8 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Strategic Consulting Services: Prescient operates as a science and insight-led development and commercialization partner for pharma and biotech companies. Engagements are project-based consulting engagements, typically tailored and led by senior executives. With 85% recurrent business and an average of 7 years of client partnerships, revenue is generated through ongoing consulting engagements across the drug lifecycle, from preclinical stage to loss of exclusivity.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Core offering

Prescient Healthcare Group is a science and insight-led development and commercialization partner for pharmaceutical and biotech companies. It delivers integrated consulting engagements across the drug lifecycle—from preclinical through loss of exclusivity—covering customer understanding, competitive intelligence, early asset strategy, scientific and medical affairs strategy, brand building and commercialization, and value demonstration and market access, supported by proprietary AI-enabled analytical tools.

Product overview

Prescient Healthcare Group is a science and insight-led development and commercialization partner offering a platform of integrated consulting services for biopharma companies. The offering comprises six core service modules: Customer Understanding (primary market research), Competitive Intelligence (AI-enabled monitoring and analysis), Early Asset Strategy/NPP (new product planning), Scientific Strategy (medical affairs), Brand Building and Commercialization, and Value Demonstration and Market Access. These are complemented by proprietary analytical tools including BrandFit (brand performance assessment) and ConferenceFit (conference intelligence). Following recent acquisitions of Uptake Strategies (launch excellence) and Dolon (pricing and market access), the platform provides comprehensive lifecycle support from preclinical development through loss of exclusivity.

Differentiator

Problem solved

Functional benefit

Brands

• Uptake: Part of Prescient; a global healthcare consultancy providing commercial and launch excellence expertise.
• Dolon

Products and services

• Customer Understanding Strategic primary market research combining behavioral science with healthcare expertise to uncover stakeholder needs, behaviors, and decision drivers for global biopharmaceutical clients.
• Competitive Intelligence Evidence-based competitive strategy and monitoring services powered by a proprietary AI-enabled platform, including competitive monitoring programs, simulation workshops, benchmarking, clinical analytics, primary intelligence, and conference coverage for biopharma clients.
• Early Asset Strategy (NPP) New product planning and early asset strategy consulting for biopharma clients, including early asset vision development, future world modeling, TPP development and testing, demand assessment, and opportunity sizing to guide go/no-go decisions.
• Scientific Strategy Medical affairs and scientific strategy consulting for biopharma clients from early integration with R&D through evidence generation planning, including medical advisory board programs, scientific narrative development, stakeholder engagement strategy, and medical affairs organizational optimization.
• Brand Building and Commercialization Strategic brand development and commercialization services for biopharma clients, including brand strategy, positioning, competitor response strategy, and LCM/LOE planning, combining behavioral insight, commercial expertise, and strategic facilitation.
• Value Demonstration and Market Access End-to-end market access support for biopharma clients, including RWE study design and execution, epidemiology analyses, payer insights, and innovative contracting solutions to help generate evidence and demonstrate value for pricing and reimbursement navigation.
• BrandFit Quantitative holistic assessment of brand campaigns compared with key competitors, evaluating customer engagement, perceptions, and message comprehension within the context of environmental drivers, barriers, and competitors; delivers rapid insights through an intuitive dashboard for biopharma marketers.
• ConferenceFit Rapid assessment of opportunities or threats arising from data readouts at conferences by capturing customer reactions, impact on perceptions within the marketplace, and likely future behaviors; combines competitive intelligence with bespoke primary market research for biopharma clients.
• Dolon (Value, Pricing and Access Practice) Strategic pricing and market access consultancy specializing in rare diseases and oncology, providing evidence-based strategies, pricing, and policy positions to support patient access to innovative medicines globally; operates as a dedicated practice within Prescient following its 2026 acquisition.
• Uptake Strategies Global healthcare consultancy providing commercial and launch excellence expertise for pharmaceutical and biotech clients, adding complementary medical, commercial, and strategic practices to Prescient's platform following its 2026 acquisition.

Quantifiable outcome

• 85% of business is recurrent, with average client partnerships lasting 7 years
• +1 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Dolon (Acquired)coreStrategic or Co-development Partner · 30 March 2026London-based strategic pricing and market access consultancy specializing in rare diseases and oncology. Dolon joins as a dedicated Value, Pricing and Access practice working alongside Prescient's established teams, delivering comprehensive support for complex challenges across the product lifecycle. The acquisition enhances Prescient's capabilities in strategic pricing, market access, and support across the drug lifecycle.
• Uptake Strategies (Acquired)coreStrategic or Co-development Partner · 9 January 2026Uptake Strategies Ltd, a global healthcare consultancy, was acquired to add highly complementary commercial and launch expertise to Prescient's platform. CEO Stephanie Hall joined the Prescient Board to co-lead the combined Commercial Practice. The deal supports Prescient's strategic growth ambitions focused on expanding global reach and innovation.
• UN Global CompactminorOthers · 1 January 2025Prescient became a participant in the UN Global Compact in 2023, aligning operations and strategies with 10 universally accepted principles in human rights, labor, environment and anti-corruption.
• B Lab (B Corp)minorOthers · 1 January 2025Prescient achieved B Corp certification in 2025, joining a global community of businesses committed to high standards of social and environmental performance, accountability and transparency.
• Strategic North (Acquired)coreStrategic or Co-development Partner · 2 March 2022Acquired in March 2022 to expand Prescient's capabilities in commercial strategy, stakeholder insights, and global market development, strengthening Prescient's position in the biopharma industry and enabling more integrated services.
• EcoVadisminorOthers · 1 January 2022EcoVadis assesses Prescient's sustainability performance annually across Environment, Labor & Human Rights, Ethics and Sustainable Procurement. Prescient has completed the EcoVadis sustainability assessment since 2022 and earned a medal each year.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Putnam Associates: Specialized biopharma strategy consulting firm serving top global pharma and biotech clients across the drug lifecycle. Closely comparable to Prescient in client base (top 25 biopharma), service mix (commercial strategy, market access, CI), and senior-led engagement model.
• ClearView Healthcare Partners: Pharma and biotech strategy consulting boutique focused on commercial strategy, new product planning, and competitive intelligence for global biopharma. Highly comparable to Prescient's Customer Understanding, CI, and Early Asset Strategy modules.
• Health Advances: Healthcare strategy consultancy advising biopharma, medtech, and diagnostics clients on commercial strategy, portfolio prioritization, and market access. Comparable to Prescient in scientific rigor, senior-led model, and biopharma focus.
• Triangle Insights Group: Specialized pharma and biotech strategy consulting firm with deep therapeutic area expertise across oncology and rare disease. Closely comparable to Prescient's scientific strategy, early asset strategy, and competitive intelligence offerings.
• Cello Health (now Cello Group): Healthcare-focused strategy and consulting firm offering commercial strategy, market access, and CI services to global biopharma. Comparable to Prescient in service breadth across the drug lifecycle and biopharma client focus.

Broad incumbents

• ZS Associates: Large global consulting firm with one of the deepest pharma commercial practices, covering sales, marketing, CI, and AI-driven analytics. Comparable to Prescient as a competitor for pharma commercial strategy and CI mandates, but operating at significantly larger scale and broader scope.
• IQVIA: Global CRO and life sciences services giant with a sizeable consulting and analytics arm serving most of the top 25 biopharma. Comparable to Prescient in serving the same blue-chip client base across the drug lifecycle, but at vastly greater scale and broader service portfolio.
• L.E.K. Consulting: Global strategy consulting firm with a sizable life sciences practice covering pharma, biotech, and medtech. Comparable to Prescient in biopharma strategic engagements and senior-led model, but with broader sector coverage and larger global footprint.
• McKinsey & Company (Pharma Practice): Global management consultancy with a deep pharma and life sciences practice serving the largest biopharma clients worldwide. Comparable to Prescient as a competitor for top-tier pharma strategy mandates, but with vastly broader capabilities and global resourcing.

Emerging players

• Charles River Associates (Life Sciences Practice): Global consulting firm with a life sciences practice focused on commercial strategy, pricing, and market access for pharma and biotech. Comparable to Prescient in pricing/market access and commercial strategy, though operating across broader industries.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/prescient-healthcare-group
• Xx.com/prescient_hg
• Facebookfacebook.com/PrescientHG

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries3 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Prescient Healthcare Group